Therapeutics News and Research

RSS
Clinical data on CXA-101 to be presented at ICAAC

Clinical data on CXA-101 to be presented at ICAAC

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Clinical data emphasizing on efficacy and potency of torezolid to be presented

InfraReDx to display Lipiscan at TCT scientific meeting

InfraReDx to display Lipiscan at TCT scientific meeting

New findings could yield effective therapies for multiple sclerosis

New findings could yield effective therapies for multiple sclerosis

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Oral NKTR-118 has low risk for mediating significant drug-drug interactions

Alcon to acquire ESBATech AG

Alcon to acquire ESBATech AG

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Signum Biosciences awarded $1.6 million SBIR Phase II grant

Mayo study raises hope for treating multiple sclerosis

Mayo study raises hope for treating multiple sclerosis

Wisconsin researchers identify the genetic region responsible for cardiovascular collapse during anesthesia

Wisconsin researchers identify the genetic region responsible for cardiovascular collapse during anesthesia

USPTO allows Isis an additional patent for single-stranded RNAi technology

USPTO allows Isis an additional patent for single-stranded RNAi technology

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

Pluristem begins enrollment following FDA approval for clinical trials of its PLX-PAD stem cell product

BioOhio and GCIC launch Ohio Bioscience Resource Directory

BioOhio and GCIC launch Ohio Bioscience Resource Directory

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Amylin and Biocon collaborate to develop a peptide therapeutic for treating diabetes

Phase 3 trial of ataluren commences

Phase 3 trial of ataluren commences

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics demonstrates Pepducin efficacy

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

CytRx granted patent for molecular chaperone amplifier drug candidate

CytRx granted patent for molecular chaperone amplifier drug candidate

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

Acceleron's Phase 1 trial of ACE-031 reveals its potential in treating neuromuscular diseases

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist

FDA approves Ascenta's IND for AT-406 multi-IAP antagonist